Research programme: covalent immune recruiters based therapies - Anna Biosciences
Latest Information Update: 19 Jul 2021
At a glance
- Originator Anna Biosciences
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Neurodegenerative disorders